

Autocertificazione assenza di conflitto di interessi

La sottoscritta dott.ssa Alessia Alunno, nata a Città di Castello (PG) il 25/09/1982, residente [REDACTED]
[REDACTED] in qualità di: *resp. scientifico ed ECM* del programma FA ANNALS
OF RHEUMATIC DISEASES - FOCUS ON ARTRITE REUMATOIDE, ARTRITE PSORIASICA E SPONDILOARTRITE ASSIALE
2023;

ai sensi dell'art. 3.3 sul Conflitto di Interessi, pag. 18,19 dell'Accordo Stato-Regione del 19 aprile 2012, per conto del
Provider Infomedica (n. 3 - accreditamento standard)


DICHIARA

che negli ultimi due anni non ha avuto rapporti anche di finanziamento con soggetti portatori di interessi commerciali
in campo sanitario.

Torino, 17 novembre 2022

In fede,

Dott.ssa **Alessia Alunno**



PERSONAL INFORMATION

ALESSIA ALUNNO, MD PhD



Gender Female | Date of birth 25/09/1982 | Nationality Italian

CURRENT POSITION

Postdoctoral Researcher and Consultant Rheumatologist

Internal Medicine and Nephrology Division, Department of Clinical Medicine, Life, Health and Environmental Sciences (MeSVA), University of L'Aquila and ASL1 Avezzano-Sulmona-L'Aquila, L'Aquila, Italy

MAIN RESEARCH INTERESTS

Basic & Translational research

Rheumatic and musculoskeletal diseases, with particular focus on connective tissue diseases and chronic inflammatory arthritis:

- Novel auto-antibodies and their diagnostic and/or prognostic role
- B and T lymphocyte subpopulations in the pathogenesis of RMDs
- Endothelial turnover markers
- Histopathological features of minor salivary glands in primary Sjögren's syndrome and their prognostic implications
- Therapeutic application of umbilical cord Wharton jelly-derived mesenchymal stem cells from healthy females in experimental models of RMDs.

Clinical research

- Cardiovascular risk in RMDs
- Nutrition in RMDs
- Optimization of the use of patient-reported outcomes in young people with RMDs
- e-Health

EDUCATION AND TRAINING

October 2013–October 2017

PhD in Medical Biotechnology (Excellent with praise)

University of Perugia, Italy

Thesis title: "Mesenchymal stem cells (MSCs) in systemic and autoimmune diseases in mouse models and humans: potential biotechnological application for therapeutic purposes". Supervisor: Prof Roberto Gerardi defended on 5 April 2017

March 2008–March 2012

Postgraduate Rheumatology Training Program (50/50 with praise)

Rheumatology Unit, Department of Medicine, University of Perugia, Italy

Thesis title: "Regulatory and Thelper 17 subpopulations in the pathogenesis of Sjögren's syndrome". Supervisor: Prof Roberto Gerardi, defended on 20 March 2012

October 2008–October 2009

Research Fellowship in Experimental Rheumatology

Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, UK.
Supervisor: Prof Costantino Pitzalis

- Flow Cytometry
- Immunohistochemistry
- Immunofluorescence
- PCR
- Magnetic cell sorting
- Cell culture
- Biomedical statistics

9th October 2007

Medical Degree (110/110 with praise)

University of Perugia, Italy

Thesis title: "Regulatory and effector T cells in rheumatic autoimmune diseases: role of glucocorticoid-induced TNFR-related gene (GITR)". Supervisor: Prof Roberto Gerardi

16th July 2001

High school degree (100/100)

Liceo Scientifico "Leonardo da Vinci", Umbertide, Perugia, Italy

TEACHING ACTIVITIES

March 2012-to date

Supervisor of medical and dentistry students

University of Perugia, Italy and University of L'Aquila, Italy

Supervision and mentoring of last year students during the preparation of the degree thesis

January 2016–June 2021

Rheumatology Teacher for medical students

Medicine School, University of Perugia, Italy, Medicine School, University of L'Aquila

4th year Medicine Students preparation to the exam of 'Systemic Pathology V'

January 2016-to date

Rheumatology Teacher for rheumatology and internal medicine trainees

Tosco-Umbra Postgraduate Rheumatology Training Program, University of Pisa

Internal Medicine Postgraduate Training Program, University of L'Aquila

Rheumatology trainees at different postgraduate year

October 2017–June 2021

Faculty member of the EULAR School of Rheumatology

Postgraduate Classroom (Head: Prof Maurizio Cutolo) People with Arthritis and Rheumatism in Europe (PARE) Classroom (Head: Mr Dieter Weck). In the latter, Medicine Advisor of the EULAR online course for patient education partners

October 2018–June 2021

Supervisor of PhD students

Supervision and mentoring of students undertaking the PhD programme in Translational Medicine, at the University of Perugia

PERSONAL SKILLS

Mother tongue

Italian

Other language

| | UNDERSTANDING | | SPEAKING | | WRITING |
|---------|---------------|---------|--------------------|-------------------|---------|
| | Listening | Reading | Spoken interaction | Spoken production | |
| English | C2 | C2 | C2 | C2 | C2 |

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user

Digital competence

- Good command of office suite
- Good command of statistical analysis softwares (GraphPad, SPSS, MedCalc, STATA)
- Good command of image analysis and photo editing software (IS Capture, Adobe Photoshop)
- Good command of laboratory software (Cell QuestPro (Becton Dickinson), FCAP Array (Becton Dickinson))

Peer-reviewing activity

Currently serving as reviewer for the following journals:

- The New England Journal of Medicine
- Annals of the Rheumatic Diseases
- Nature Reviews Rheumatology
- Lancet Rheumatology
- Rheumatology (Oxford)
- Expert Reviews of Clinical Immunology
- Frontiers in Immunology
- The Journal of Rheumatology
- Clinical and Experimental Rheumatology
- Therapeutic Advances in Musculoskeletal Disease
- International Journal of Rheumatic Diseases
- Rheumatology International
- RMD Open
- Medicine (Baltimore)
- Autoimmunity
- Mediators of Inflammation
- Cellular Immunology
- Journal of Oral Pathology and Medicine

Editorial activity

- Annals of the Rheumatic Diseases and RMD Open (Society of Medical Advancers)
- BMC Rheumatology (Section Editor)
- Frontiers in Medicine-Rheumatology (Associate Editor)
- Acta Reumatologica Portuguesa (Associate Editor)
- Reumatismo, the journal of the Italian Society of Rheumatology (Section Editor)

LIST OF PUBLICATIONS

H Index=41 (Scopus)

Total citations =5232 (Scopus)

1. Carubbi F*, **Alunno A***, Santilli J, Natali L, Mancini B, Di Gregorio N, De Pinto R, Vascotto A, Grassano D, Ferrante C. Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares. RMD Open 2022;8:e002460 *shared first Authorship
2. Gustafsson L, Bianchini V, Aggostino A, Mammarella S, Saiz A, Necozione S, **Alunno A**, Ferrante C, Casaccia M, Roncone R. Twelve-month outcomes in overweight/obese users with mental disorders following a multi-element treatment including diet, physical activity, and positive thinking: The real-world "An Apple a Day" controlled trial. Front Psychiatry. 2022;13:903759
3. Carubbi F*, **Alunno A***, Carducci A, Grassano D, Ferrante C. Electrocardiographic Abnormalities in Hospitalized Patients with COVID-19 and the Associations with Clinical Outcome. J Clin Med. 2022 Sep 5;11(17):5248 *shared first Authorship
4. Ovseiko PV, Gossec L, Andreou L, Ktzi U, van Mens L, Hassan N, van der Leeden M,

- Sidd e HJ, **Alunno A**, McInnes IB, Damjanov NS, Appara y F, Ospe t C, van der Horst-Bru nsma IE, N k phorou E, Druce KL, Szekanecz Z, Sepr ano A, Avc n T, Bertas G, Schett G, Keenan AM, Po o LH, Coates LC. Gender equ ty n academ c rheumatogy, current status and potent a for mprovement: a cross-sect ona study to nform an EULAR task force. *RMD Open*. 2022 Aug;8(2):e002518.
5. Studen c P, Stamm TA, Mosor E, B n I, Caeyers N, Gossec L, Kou oumas M, N k phorou E, O sder W, Padjen I, Ram ro S, Stones S, W he mer TC, **Alunno A**. EULAR po nts to cons der for nc ud ng the perspect ve of young pat ents w th nf ammatory arthr ts nto pat ent-reported outcomes measures. *RMD Open*. 2022;8(2):e002576.
 6. Petre F, Mar an FM, **Alunno A**, Puxeddu I. Pathogenes s of rheumat d arthr ts: one year n rev ew 2022. *C n Exp Rheumato* . 2022;40(3):475-482.
 7. Sc asc a S, Fodda SG, A essandr C, **Alunno A**, Andreo L, Bar nott A, Ca garo A, Cant V, Carubb F, Cecch I, B Ch gh zo a C, Cont F, Emm G, F oravant A, F schett F, Francesch n F, Gerosa M, Hoxha A, Larosa M, Lazzaron MG, Na C, Pazzo a G, Rad n M, Raffe ner B, Ramon VL, Rub n E, Sebast an GD, Trug a S, Urban ML, Roccate o D, T ncan A. C n ca De ph on aPL Negat v zat on: Report from the APS Study Group of the Ita an Soc ety for Rheumatogy (SIR-APS). *Thromb Haemost*. 2022 do : 10.1055/a-1798-2400.
 8. Zanett A, Carrara G, Lando f G, Rozza D, Ch gh zo a CB, **Alunno A**, Andreo L, Capora R, Ger R, Sebast an GD, Va es n G, S n gag a L, Raffe ner B, Lomater C, Capro M, Fred M, Romeo N, Cuomo G, Vadacca M, Sc r è CA; CONTROL-19 study by the Ita an Soc ety for Rheumatogy. Increased COVID-19 morta ty n pat ents w th rheumat c d seases: resu ts from the CONTROL-19 study by the Ita an Soc ety for Rheumatogy. *C n Exp Rheumato* . 2022 do : 10.55563/c nexprheumato /fmyozh.
 9. Najm A, Costant no F, A vern n S, **Alunno A**, B anch E, B gna J, Boyce B, Cañete JD, Carubb F, Durez P, Fonseca JE, Just SA, Largo R, Manzo A, Maybury M, Naredo E, Orr C, P tza s C, R ve ese F, Romão VC, van Rompay J, Tas SW, Ve a DJ, D'Agost no MA, F er A. EULAR po nts to cons der for m n ma report ng requ irements n synov a t ssue research n rheumatogy. *Ann Rheum D s*. 2022 do : 10.1136/annrheumd s-2021-221875
 10. Landewé RBM, Kroon FPB, **Alunno A**, Najm A, B j sma JW, Burmester GR, Capora R, Combe B, Conway R, Curt s JR, E kayam O, Gossec L, He jstek MW, Haupt L, Iagnocco A, Isaacs JD, Juhász IÁ, Makr S, Mar ette X, McInnes IB, Mehta P, Mue er-Ladner U, Schu ze-Koops H, Smo en JS, W ek D, W nthrop KL, Navarro-Compán V, Machado PM. EULAR recommendat ons for the management and vacc nat on of peop e w th rheumat c and muscu oske eta d seases n the context of SARS-CoV-2: the November 2021 update. *Ann Rheum D s*. 2022 do : 10.1136/annrheumd s-2021-222006
 11. **Alunno A**, Mavragan CP, Carubb F. Ed tor a : Management of Sjögren's Syndrome. *Front Med (Lausanne)*. 2022;8:836182
 12. **Alunno A**, R ve ese F, Lauper K, A etaha D, Buch MH, Gossec L, Mand P, Machado PM, Ospe t C, Mo to A, Ram ro S, N k phorou E, Sepr ano A. EMerg ng EULAR NETWORK (EMEUNET): a remarkab e foundat on for the future. *RMD Open*. 2021;7(3):e001962. do : 10.1136/mdopen-2021-001962.
 13. Dejaco C, Machado PM, Carubb F, Bosch P, Ters ev L, Tamborr n G, Sconf enza LM, Sc r è CA, Ruetten S, van Rompay J, Proft F, P tza s C, Obradov M, Moe RH, Mascarenhas VV, Ma att a C, K auser AS, Kent A, Jans L, Hartung W, Hammer HB, Duftner C, Ba nt PV, **Alunno A**, Bara akos X. EULAR po nts to cons der for the use of mag ng to gu de ntervent ona procedures n pat ents w th rheumat c and muscu oske eta d seases (RMDs). *Ann Rheum D s*. 2022;81(6):760-767.
 14. Carubb F, Bosch P, Machado PM, Sc r è CA, **Alunno A**, Proft F, Bara akos X, Dejaco C. Current Pract ce of Imag ng-Gu ded Intervent ona Procedures n Rheumat c and Muscu oske eta D seases: Resu ts of a Mu t nat ona Mu t d sc p nary Survey. *Front Med (Lausanne)*. 2021 Nov 22;8:779975
 15. Kroon FPB, Najm A, **Alunno A**, Schoones JW, Landewé RBM, Machado PM, Navarro-Compán V. R sk and prognos s of SARS-CoV-2 nfect on and vacc nat on aga nst SARS-CoV-2 n rheumat c and muscu oske eta d seases: a systemat c terature rev ew to nform EULAR recommendat ons. *Ann Rheum D s*. 2021 do : 10.1136/annrheumd s-2021-221575.
 16. Carubb F*, **Alunno A***, Ma F, Mercur A, Centorame D, C po on J, Mar an FM, Ross M, Barto on E, Grass D, Ferr C. Adherence to the Med terranean d et and the mpact on c n ca features n pr mary Sjögren's syndrome. *C n Exp Rheumato* . 2021 Nov 29. On ne ahead of pr nt. *shared frst Authorsh p
 17. **Alunno A**, Najm A, Mar ette X, De Marco G, Emme J, Mason L, McGonag e DG, Machado PM. Immunomodu atory therap es for the treatment of SARS-CoV-2 nfect on: an update of the systemat c terature rev ew to nform EULAR po nts to cons der. *RMD Open*. 2021 Oct;7(3):e001899.
 18. Carubb F, **Alunno A**, Leone S, D Gregor o N, Manc n B, V sc do A, De P nto R, Cogna S, Grass D, Ferr C. Per card ts after SARS-CoV-2 Infect on: Another Pebb e n the Mosa c of Long COVID? *V ruses*. 2021 Oct 4;13(10):1997

19. Cafaro G, Perricone C, Rocucci I, Bursi R, Cavacchi S, **Alunno A**, Carubbi F, Gerardi R, Barton E. Traditional and disease-related non-computed variables affect algorithms for cardiovascular risk estimation in Sjögren's syndrome and rheumatoid arthritis. *Clin Exp Rheumatol*. 2021 Oct 18. Online ahead of print.
20. Umar HM, Sander RD, **Alunno A**, Matucci-Cernic M, Hughes M. Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review. *Semin Arthritis Rheum*. 2021 Sep 16;51(6):1200-1204.
21. **Alunno A**, Najm A, Machado PM, Bertheussen H, Burmester GR, Carubbi F, De Marco G, Gacome R, Hermene O, Isaacs JD, Koné-Paut I, Magro-Checa C, McInnes IB, Meron PL, Quartuccio L, Ramanan AV, Ramos-Casas M, Rodríguez Carrón J, Schuize-Koops H, Stamm TA, Tas SW, Terrer B, McGonagle DG, Marlette X. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. *Ann Rheum Dis*. 2021 doi: 10.1136/annrheumdis-2021-221366
22. Studenci P, **Alunno A**, Seghart D, Bang H, Aetaha D, Bümm S, Hasacher H, Smolen JS, Gerardi R, Steiner G. Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discernable adaptive capacity towards early rheumatoid arthritis. *Ther Adv Musculoskelet Dis*. 2021 doi: 10.1177/1759720X211022533.
23. Barton E, Perricone C, Cafaro G, **Alunno A**, Gerardi R. The facts and fictions of precision medicine in autoimmune diseases: should we learn to approach the response? *Rheumatology (Oxford)*. 2021 doi: 10.1093/rheumatology/keab715
24. van Onna M, Ramiro S, Haines C, Hond-Fischer M, da Silva JAP, Dudler J, Edwards C, **Alunno A**, Nkphorou E, Faizon L, Svera F; Working group on Development of a EULAR portfolio for Rheumatology training. EULAR portfolio for Rheumatology training: a EULAR School of Rheumatology initiative. *RMD Open*. 2021 Jun;7(2):e001684
25. Nada DW, Moghazy A, Alami AE, **Alunno A**, Ibrahim AM. Short-Term Outcomes and Predictors of Effectiveness of Tocilizumab in Systemic Juvenile Idiopathic Arthritis: A Prospective Cohort Study. *Front Med (Lausanne)*. 2021 May 10;8:665028
26. Testa D, Cavacchi S, Petrelli F, Gannini D, Balsa S, **Alunno A**, Puxeddu I. One year review 2021: pathogenesis of rheumatoid arthritis. *Clin Exp Rheumatol*. 2021 May-Jun;39(3):445-452
27. Najm A, **Alunno A**, Gwinnutt JM, Welch C, Berenbaum F. Efficacy of intra-articular corticosteroid injections in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. *Joint Bone Spine*. 2021 Jun;88(4):105198.
28. **Alunno A**, Carubbi F, Ferraccioli G, Gerardi R, Barton E. Different clinical presentations of primary Sjögren's syndrome: Not only a matter of age. *Joint Bone Spine*. 2021 Jun;88(4):105191.
29. Boonen A, Putrik P, Marques ML, **Alunno A**, Abasolo L, Beaton D, Betteridge N, Björk M, Boers M, Boteva B, Fautrel B, Guemina F, Mateus EF, Nkphorou E, Péntek M, Pimente Santos F, Severens JL, Verstappen SMM, Walker-Bone K, Waman JK, Ter Wee MM, Westhovens R, Ramiro S. EULAR Points to Consider (PTC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. *Ann Rheum Dis*. 2021 doi: 10.1136/annrheumdis-2020-219523
30. Di Bartolomeo S, **Alunno A**, Carubbi F. Respiratory Manifestations in Systemic Lupus Erythematosus. *Pharmaceuticals (Basel)*. 2021 Mar 18;14(3):276
31. **Alunno A**, Carubbi F, Barton E, Grass D, Ferraccioli G, Gerardi R. Diet in Rheumatoid Arthritis versus Systemic Lupus Erythematosus: Any Differences? *Nutrients*. 2021 Feb 27;13(3):772.
32. Carubbi F, Savat L, **Alunno A**, Maggi F, Borghese E, Maran R, Ma F, Paoletti M, Ferraccioli G, Cognigni S, Grass D. Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. *Sci Rep*. 2021 Mar 1;11(1):4863
33. Studenci P, Karfent S, **Alunno A**. The past, present and future of e-health in Rheumatology. *Joint Bone Spine*. 2021 doi: 10.1016/j.jbspn.2021.105163.
34. **Alunno A**, Najm A, Marlette X, De Marco G, Emme J, Mason L, McGonagle DG, Machado PM. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. *Ann Rheum Dis*. 2021 doi: 10.1136/annrheumdis-2020-219725.
35. Najm A, **Alunno A**, Marlette X, Terrer B, De Marco G, Emme J, Mason L, McGonagle DG, Machado PM. Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. *RMD Open*. 2021 Feb;7(1):e001549.
36. **Alunno A**, Najm A, Machado PM, Bertheussen H, Burmester GR, Carubbi F, De Marco G, Gacome R, Hermene O, Isaacs JD, Koné-Paut I, Magro-Checa C, McInnes I, Meron PL, Quartuccio L, Ramanan AV, Ramos-Casas M, Rodríguez Carrón J, Schuize-Koops H, Stamm TA, Tas SW, Terrer B, McGonagle DG, Marlette X. EULAR points to consider on

- pathophysiology and use of immunomodulatory therapies in COVID-19. *Ann Rheum Dis*. 2021 do : 10.1136/annrheumdis-2020-219724
37. Marques ML, **Alunno A**, Boonen A, Ter Wee MM, Fa zon L, Ram ro S, Putr k P. Methodology aspects of design, analysis and reporting of studies with work participant as an outcome domain in patients with inflammatory arthritis: results of two systematic literature reviews informing EULAR points to consider. *RMD Open*. 2021 Feb;7(1):e001522.
 38. Mosor E, Studen c P, **Alunno A**, Padjen I, O sder W, Ram ro S, B n I, Caeyers N, Gossec L, Kououmas M, Nkphorou E, Stones S, W he mer TC, Stamm TA. Young people's perspectives on patient-reported outcome measures in inflammatory arthritis: results of a multicentre European qualitative study from a EULAR task force. *RMD Open*. 2021 Jan;7(1):e001517.
 39. Carubb F, **Alunno A**, Ferr C, Ger R, Barto on E. The Impact of SARS-CoV-2 Outbreak on Primary Sjögren's Syndrome: An Italian Experience. *Front Med (Lausanne)*. 2020 Dec 7;7:608728.
 40. **Alunno A**, Carubb F. Unmet needs in primary Sjögren's syndrome and the never-ending quest for the perfect biomarker. *Acta Reumatol Port*. 2020 Jun 31;45(Jun-Sep (3)):167-169.
 41. **Alunno A**, Leone MC, Barto on E, Ger R, Carubb F. New insights on lymphoma and lymphomagenesis in primary Sjögren's Syndrome. *Pain Management*. 2020 do : 10.23736/S0031-0808.20.04079-3
 42. **Alunno A**, Ger R, Barto on E. Comment on: Equating rights in autoimmunity: is Sjögren's syndrome ever 'secondary'? *Rheumatology (Oxford)*. 2021 Jan 5;60(1):e32-e33.
 43. Dejaco C, **Alunno A**, Bjsma JW, Boonen A, Combe B, F nckh A, Machado PM, Padjen I, S vera F, Stamm TA, Buttgere t F. Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. *Ann Rheum Dis*. 2020 do : 10.1136/annrheumdis-2020-218697.
 44. Gandofo S, Fabro C, Kapsogeorgou E, Co afrancesco S, Ferro F, Barto on E, Quartuccio L, Goues A, Pror R, **Alunno A**, Cont F, Va es n G, Gacome R, Ba d n C, Ger R, Tzoufas AG, De V ta S. Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: results in independent cohorts. *Clin Exp Rheumatol*. 2020 Jun-Aug;38 Suppl 126(4):189-194.
 45. Carubb F, **Alunno A**, Confort A, Rccucc I, D Co a I, Barto on E, Ger R. Characterisation of articular manifestations in primary Sjögren's syndrome: clinical and magnetic features. *Clin Exp Rheumatol*. 2020 Jun-Aug;38 Suppl 126(4):166-173.
 46. Pavych V, D Muzo C, **Alunno A**, Carubb F. Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting. *Front Med (Lausanne)*. 2020 Sep 8;7:534. do : 10.3389/fmed.2020.00534.
 47. Chghzoa CB, Crsafu F, Hoxha A, Carubb F, Be an M, Mont S, Costa L, Ba d C, Rad n M, Pra no E, Co etto LA, Pregnato F, Sc asc a S, Sa nagh PP, Be s E, Ramon V, Quartuccio L, **Alunno A**, Gerosa M, Andreo L; SIRyoung. Psychosocial burden in young patients with primary antiphospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). *Clin Exp Rheumatol*. 2020 Sep 16. Online ahead of print.
 48. Carubb F, **Alunno A**. The Serological Status Affects the Prognostic Role of Sarcoidosis and Histology in Primary Sjögren Syndrome. *J Rheumatol*. 2020 do : 10.3899/jrheum.200350
 49. Najm A, Kostne M, Pau ng JD, Ferre ra AC, Stevens K, Sm th E, Egu uz-Grac a I, Studen c P, Rodríguez-Carr o J, Ram ro S, **Alunno A**, R chez C, Nkphorou E, Seprano A. Multicenter collaborative study among young specialists: results of an international survey by the emerging EULAR network and other young organizations. *RMD Open* 2020 do : 10.1136/rmdopen-2020-001398
 50. **Alunno A**, Najm A, S vera F, Ha nes C, Fa zon L, Ram ro S. Assessment of competences in rheumatology training: results of a systematic literature review to inform EULAR points to consider. *RMD Open*. 2020 Sep;6(2):e001330.
 51. S vera F, **Alunno A**, Najm A, Av n T, Bara akos X, Bjsma JW, Badreh S, Burmester G, C kes N, Da S va JA, Damjanov N, Dougados M, Dud er J, Edwards CJ, Iagnocco A, Lote F, Nkphorou E, van Onna M, Stones SR, Vass opoulos D, Ha nes C, Ram ro S. 2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. *Ann Rheum Dis*. 2020 do : 10.1136/annrheumdis-2020-218015.
 52. Sc è CA, Carrara G, Zanett A, Lando f G, Ch ghzoa C, **Alunno A**, Andreo L, Capora R, Ger R, Sebastian GD, Va es n G, S n gag a L; Italian Registry of the Italian Society for Rheumatology (CONTROL-19). COVID-19 in rheumatoid diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). *Clin Exp Rheumatol*. 2020 Jun-Aug;38(4):748-753.
 53. Najm A, **Alunno A**, S vera F, Ram ro S, Ha nes C; Working Group on Training in Rheumatology across Europe. Strategies for the assessment of competences during rheumatology training across Europe: results of a qualitative study. *RMD Open*. 2020

- Ju ;6(2):e001183.
54. Rodríguez-Carrío J, Putrık P, Gwinnutt J, Seprano A, **Alunno A**, Ramiro S, Lepe J, Nikphorou E; EMEUNET Working Group. Mentorng for postdoctoral researchers in rheumatology: the Emergng EULAR Network (EMEUNET) post-doc mentorng programme. *RMD Open*. 2020 Feb;6(1):e001139.
 55. **Alunno A**, Bston O, Ger R. Beware of wolves n sheep's clothng: immune ce past cty and nstab ty n health and dsease. *Ann Rheum D s*. 2020 do : 10.1136/annrheumd s-2020-218094.
 56. **Alunno A**, Carubb F, Rodríguez-Carrío J. Storm, typhoon, cyc one or hurr cane n pat ents wth COVID-19? Beware of the same storm that has a dfferent or g n. *RMD Open*. 2020 May;6(1):e001295.
 57. Gann n D, Antonucc M, Petre F, B a S, **Alunno A**, Puxeddu I. One year n rev ew 2020: pathogenes s of rheumato d arthr t s. *C n Exp Rheumato* . 2020 May-Jun;38(3):387-397.
 58. **Alunno A**, Bston O, Bon fac o AF, Ger R. Autoant bod es and nterst ta ung d sease n rheumato d arthr t s: towards a 'm x-and-match' approach? *Ann Rheum D s*. 2020 do : 10.1136/annrheumd s-2020-217410
 59. **Alunno A**, Nikphorou E, Ph ppou E, Da en C, Wek D, Kououmas M, Cuto o M. Nutr t on n RMDs: s t rea y food for thought? Focus on rheumato d arthr t s. *BMC Rheumatogy* 2019 n press
 60. Esposito M, Carubb F, Gunta A, **Alunno A**, Gacome R, Fargno MC. Certo zumab pego for the treatment of psor at c arthr t s and paque psor as s. *Expert Rev C n Immuno* . 2020 Feb;16(2):119-128.
 61. La Pag a GMC, Sanchez-Pernaute O, **Alunno A**, Martínez-Becerra MJ, Romero-Bueno F, Recuero S, Borges PE, Mah o-Fernández I, Garr do J, Ger R, Herrero-Beaumont G, Naredo E. Ultrasound sa vary g and nvement n Sjogren's syndrome vs. other connect ve tssue d seases: s t autoant body and g and dependent? *C n Rheumato* . 2019 do : 10.1007/s10067-019-04780-2
 62. Cafaro G, Barto on E, **Alunno A**, Bston O, Cpran S, Top n F, Ger R. A Pate et's Gu de to Synov t s. *Isr Med Assoc J*. 2019;21(7):454-459
 63. Barto on E, Ba d n C, Ferro F, **Alunno A**, Carubb F, Cafaro G, Bombard er S, Ger R, Gross E. App cat on of artfca neura network (ANN) anays s n the eva uat on of card ovascu ar r sk n pr mary Sjögren's syndrome: a nove pathogenet c scenar o? *C n Exp Rheumato* 2019;37 Supp 118(3):133-139
 64. **Alunno A**, Carubb F, Barto on E, Cpran P, Gacome R, Ger R. The ka e doscope of neuro og ca man festat ons n pr mary Sjögren's syndrome. *C n Exp Rheumato* 2019 n press
 65. **Alunno A**, Padjen I, Fanour ak s A, Boumpas DT. Pathogen c and therapeut c re evance of JAK/STAT s gna ng n systemc upus erythematosus: ntegrat on of d st nct nf ammatory pathways and the prospect of the r nh b t on wth an ora agent. *Ce s* 2019 8(8), 898
 66. Carubb F, **Alunno A**, Ger R, Gacome R. Post-Trans at ona Mod fcat ons of Prote ns: Nove Ins ghts n the Auto mmune Response n Rheumato d Arthr t s. *Ce s* 2019;8(7):657
 67. Barto on E, **Alunno A**, Ger R. The dark s de of Sjögren's syndrome: the poss be pathogen c ro e of nf ect ons. *Curr Op n Rheumato* . 2019;31(5):505-511
 68. Croa C, Burs R, Suter a D, Petre F, **Alunno A**, Puxeddu I. One year n rev ew 2019: pathogenes s of rheumato d arthr t s. *C n Exp Rheumato* . 2019;37(3):347-357
 69. Barto on E, **Alunno A**, Cafaro G, Va ent n V, Bston O, Bon fac o AF, Ger R. Subc nca Atheroseros s n Pr mary Sjögren's Syndrome: Does Inf ammat on Matter? *Front Immuno* . 2019;10:817
 70. Barto on E, Bston O, **Alunno A**, Cavagna L, Na otto L, Ba d n C, Pror R, Fschett C, Fred M, Quartucco L, Carubb F, Montecucco C, Dor a A, Mosca M, Va es n G, Francesch n F, De V ta S, Gacome R, Mrabe G, B n V, Gabre A, Catass C, Ger R. Ce ac D sease Prevaence s Increased n Pr mary Sjögren's Syndrome and D ffuse Systemc Sc eros s: Lessons from a Large Mu t -Center Study. *J C n Med*. 2019;8(4)
 71. Francsc D, P rro M, Scharo E, Mannar no MR, Cpran S, Bancon V, **Alunno A**, Bagag a F, Bston O, Fa c ne E, Bury L, Ger R, Mannar no E, De Cater na R, Ba de F. Marav roc Intens fcat on Modu ates Atheroserot c Progress on n HIV-Suppressed Pat ents at H gh Card ovascu ar R sk. A Random zed, Crossover P ot Study. *Open Forum Infect D s*. 2019;6(4):ofz112
 72. Fanour ak s A, Kostopou ou M, **Alunno A**, Arnger M, Bajema I, Boet s JN, Cervera R, Dor a A, Gordon C, Govon M, Houss au F, Jayne D, Kououmas M, Kuhn A, Larsen JL, Lerstrøm K, Moron G, Mosca M, Schneider M, Smoen JS, Svenungsson E, Tesar V, Tncan A, Trodborg A, van Vo enhoven R, Wenze J, Bertas G, Boumpas DT. 2019 update of the EULAR recommendat ons for the management of systemc upus erythematosus. *Ann Rheum D s* 2019 do : 10.1136/annrheumd s-2019-215089
 73. Bon fac o AF, **Alunno A**, La Pag a GMC, Va ent n E, Leone MC, Barto on E, Ger R. Nove autoant bod es n rheumato d arthr t s. *Reumat smo* 2019;71(1):1-12

74. Carubb F, **Alunno A**, Cpran P, Coett G, Bgerna B, Manett M, D Benedetto P, Bston O, Cpo on G, Lakou V, Ruscit P, Barto on E, Gacome R, Ger R. Different operators and histologic techniques in the assessment of germinal center structures in primary Sjögren's syndrome in non-sarcomatous glands. *PLoS One*. 2019;14(1):e0211142
75. Barto on E, **Alunno A**, Vaentn V, Lucco F, Vaentn E, La Pag a GMC, Leone MC, Cafaro G, Marcucc E, Ger R. Targeting inflammation to prevent cardiovascular disease in chronic rheumatic diseases: myth or reality? *Front Cardiovasc Med* 2018 doi: 10.3389/fcvm.2018.00177
76. Marcucc E, Barto on E, **Alunno A**, Leone MC, Cafaro G, Lucco F, Vaentn V, Vaentn E, La Pag a GMC, Bonfaco AF, Ger R. Extra-articular rheumatoid arthritis. *Reumatismo* 2018;70(4):212-224
77. Montanucc P, Pescara T, **Alunno A**, Bston O, Basta G, Cafare R. Remission of hyperglycemia in spontaneously diabetic NOD mice upon transplant of microencapsulated human umbilical cord Wharton Jelly-derived mesenchymal stem cells (hUCMS). *Xenotransplantation* 2018 doi: 10.1111/xen.12476
78. Gacome R, Afe tra A, **Alunno A**, Barto on-Bocc E, Berard curt O, Bombard er M, Bortozz A, Capora R, Caso F, Cervera R, Chment MS, Cpran P, Cooma E, Cont F, D'Angelo S, De Vita S, D Bartomeo S, D ster O, Dor a A, Fest E, Fsher BA, Gerosa M, G o M, Guggino G, Lakou V, Margotta DPE, Meron P, Moronc G, Perosa F, Prete M, Pror R, Rebuff C, Ruscit P, Scarpa R, Shoenfeld Y, Todoert M, Urs n F, Vaes n G, Vettor S, Vita C, Tzoufas AG. Guidelines for biomarkers in autoimmune rheumatic diseases evidence based analysis. *Autoimmun Rev* 2018 doi: 10.1016/j.autrev.2018.08.003.
79. **Alunno A**, Carubb F, Stones S, Ger R, Gacome R, Barakos X. The impact of fibromyalgia in spondyloarthritis: From classification criteria to outcome measures. *Front Med (Lausanne)*. 2018;5:290
80. Cafaro G, Barto on E, Alunno A, Ger R. Platelets: a potential target for rheumatoid arthritis treatment? *Expert Rev Clin Immunol* 2018 doi: 10.1080/1744666X.2019.1544071
81. **Alunno A**, Ibba-Mannesch L, Bston O, Cpran S, Top n F, Ger R, Manett M. Angiogenic T cells in primary Sjögren's syndrome: a double-edged sword? *Clin Exp Rheumatol* 2018 [Epub ahead of print]
82. Carubb F, **Alunno A**, Ger R, Gacome R. Histopathology of salivary glands. *Reumatismo*. 2018 Oct 3;70(3):146-154. doi: 10.4081/reumatismo.2018.1053
83. D Battista M, Marcucc E, Eefante E, Trpo A, Governato G, Zucchi D, Tan C, **Alunno A**. One year review 2018: systemic lupus erythematosus. *Clin Exp Rheumatol*. 2018 Sep-Oct;36(5):763-777
84. **Alunno A**, Barto on E, Vaentn V, La Pag a GMC, Vaentn E, Leone MC, Marcucc E, Cafaro G, Bonfaco AF, Lucco F, Ger R. Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome. *Clin Exp Rheumatol*. 2018 May-Jun;36 Suppl 112(3):210-214
85. Barto on E, **Alunno A**, Vaentn V, Vaentn E, La Pag a GMC, Leone MC, Cafaro G, Marcucc E, Bonfaco AF, Lucco F, Ger R. The prevalence and relevance of traditional cardiovascular risk factors in primary Sjögren's syndrome. *Clin Exp Rheumatol*. 2018 May-Jun;36 Suppl 112(3):113-120
86. **Alunno A**, Bston O, Prates F, Top n F, Puxeddu I, Vaentn V, Cafaro G, Barto on E, Mgorn P, Ger R. Association between anti-citrullinated alpha enoase antibodies and clinical features in a cohort of patients with rheumatoid arthritis: a pilot study. *Reumatismo*. 2018;70(2):67-71
87. Cabres E, Petre F, Bonfaco AF, Puxeddu I, **Alunno A**. One year review 2018: pathogenesis of rheumatoid arthritis. *Clin Exp Rheumatol*. 2018 Mar-Apr;36(2):175-184
88. **Alunno A**, Leone MC, Gacome R, Ger R, Carubb F. Lymphoma and Lymphomagenesis in Primary Sjögren's Syndrome. *Front Med (Lausanne)*. 2018 Apr 13;5:102
89. **Alunno A**, Studenc P, Wek D, Bažová P, Aetaha D. Missing piece in the mosaic of rheumatic diseases and mental health: younger does not always mean happier. *Ann Rheum Dis*. 2018 doi: 10.1136/annrheumdis-2018-213611
90. Carubb F, **Alunno A**, Cpran P, Bston O, Scpon R, Lakou V, Ruscit P, Berard curt O, D Bartomeo S, Ger R, Gacome R. Laboratory assessment in patients with suspected rheumatic musculoskeletal diseases: challenges, pitfalls and perspectives. *Curr Rheumatol Rev*. 2018 Mar 19. doi: 10.2174/1573397114666180320113603
91. **Alunno A**, Bston O, Prates F, La Pag a GMC, Puxeddu I, Mgorn P, Ger R. Anticitrullinated alpha enoase antibodies, interstitial lung disease and bone erosion in rheumatoid arthritis. *Rheumatology (Oxford)*. 2018 May 1;57(5):850-855
92. **Alunno A**, Ger R, Gacome R, Carubb F. Clinical, epidemiological, and histopathological features of respiratory involvement in Rheumatoid Arthritis. *Bomed Res Int*. 2017;2017:7915340
93. Nkphorou E, Studenc P, **Alunno A**, Canavan M, Jan M, Berenbaum F. 'Twitter and': a brave new world? *Ann Rheum Dis*. 2018 Aug;77(8):1245-1246.

94. Mockridge J, **Alunno A**, Goodman S, Roddy E. BMC Rheumatology: a home for a rheumatology research within the BMC Series. *BMC Rheumatology*. 2017;1:1
95. **Alunno A**, Carubbi F, Gacome R, Ger R. Cytokines in the pathogenesis of rheumatoid arthritis: new payers and therapeutic targets. *BMC Rheumatology*. 2017;1:3
96. Nikphorou E, **Alunno A**, Carmona L, Kououmas M, Bjsma J, Cuto M. Patient-physician collaboration in rheumatology: a necessity. *RMD Open*. 2017 Jun 18;3(1):e000499
97. **Alunno A**, Studenic P, Nikphorou E, Bažžová P, van Neuwkoop L, Ramiro S, Carubbi F, Richez C, Caeyers N, Gossec L, Kououmas M. Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists' and EULAR Young PARE perspectives. *RMD Open*. 2017 Sep 26;3(2):e000514
98. **Alunno A**, Faccone E, Lucco F, Petto E, Bartolon E, Mom S, Mrabec G, Mancini GB, Ger R, Gresele P. Platelets contribute to the accumulation of matrix metalloproteinase type 2 in synovial fluid in osteoarthritis. *Thromb Haemostasis* 2017;117(11):2116-2124
99. **Alunno A**, Carubbi F, Bstn O, Bartolon E, Vaentn V, Ger R. Novel Therapeutic Strategies in Primary Sjögren's Syndrome. *Isr Med Assoc J*. 2017 Sep;19(9):576-580
100. Leone MC, **Alunno A**, Cafaro G, Vaentn V, Marcucci E, Bartolon E, Ger R. The clinical spectrum of primary Sjögren's syndrome: beyond exocrine glands. *Reumatismo*. 2017 Sep 21;69(3):93-100
101. Bartolon E, **Alunno A**, Ger R. Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. *Nat Rev Cardiol*. 2018 Jan;15(1):33-44
102. Manca ML, **Alunno A**, D'Amato C, Bstn O, Puxeddu I, Ger R, Mgron P, Prates F. Anticardiolipin antibodies profiling in established rheumatoid arthritis. *Joint Bone Spine*. 2018 Jun;85(4):441-445.
103. **Alunno A**, Carubbi F, Gacome R, Ger R. The challenge to interpret conflicting results and the need of a uniform definition for geriatric centres in primary Sjögren's syndrome. *Ann Rheum Dis*. 2018 Jun;77(6):e31.
104. LaPagola GMC, Leone MC, Lepr G, Vage R, Vaentn E, **Alunno A**, Tan C. One year in review 2017: systemic lupus erythematosus. *Clin Exp Rheumatol*. 2017 Jun-Aug;35(4):551-561
105. Gacome R, Afebra A, **Alunno A**, Badin C, Bartolon-Bocce E, Berarducci O, Carubbi F, Cau A, Cervera R, Ccaccia F, Cpran P, Conti F, De Vita S, D Benedetto P, Dorra A, Drosos AA, Fava EG, Gandofo S, Gatto M, Grembae RD, Lakou V, Lores R, Lubrano E, Lunardi C, Margotta DPE, Massaro L, Meroni P, Mnni A, Navarin L, Pendo no M, Perosa F, Pers JO, Prete M, Pror R, Puppo F, Quartuccio L, Ruffatti A, Rusconi P, Russo B, Sarz-Puttin P, Shoenfeld Y, Somarakis GA, Spina FR, Tnazzi E, Troiano G, Ursini F, Vaentn G, Vaesini G, Vettori S, Vita C, Tzoufas AG. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management. *Autoimmun Rev*. 2017 Sep;16(9):911-924
106. **Alunno A**, Bstn O, Carubbi F, Vaentn V, Cafaro G, Bartolon E, Gacome R, Ger R. Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome. *Clin Exp Rheumatol*. 2018 May-Jun;36 Suppl 112(3):73-79
107. Angeotti F, Parma A, Cafaro G, Capecchi R, **Alunno A**, Puxeddu I. One year in review 2017: pathogenesis of rheumatoid arthritis. *Clin Exp Rheumatol*. 2017 May-Jun;35(3):368-378
108. **Alunno A**, Bstn O, Montanucci P, Basta G, Caiafore R, Ger R. Umbilical cord mesenchymal stem cells for the treatment of autoimmune diseases: beware of cell-to-cell contact. *Ann Rheum Dis*. 2018 Mar;77(3):e14
109. Bartolon E, **Alunno A**, Vaentn V, Lucco F, Vaentn E, LaPagola G, Bstn O, Ger R. Role of Inflammatory Diseases in Hypertension. *High Blood Press Cardiovasc Prev*. 2017 Dec;24(4):353-361
110. **Alunno A**, Bstn O, Manetti M, Cafaro G, Vaentn V, Bartolon E, Ger R, Lso A. Insulin-Like Growth Factor Binding Protein 6 in Rheumatoid Arthritis: A Possible Novel Chemotactic Factor? *Front Immunol*. 2017 May 18;8:554
111. Quartuccio L, Badin C, Pror R, Bartolon E, Carubbi F, **Alunno A**, Gandofo S, Coafrancesco S, Gacome R, Ger R, Vaesini G, Bombardieri S, De Vita S; GRIS Group. Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue. *J Rheumatol*. 2017 Aug;44(8):1179-1183
112. Beghe D, Isan G, Roncada P, Andrean G, Bstn O, Bertocchi M, Lupat G, **Alunno A**. Antioxidant and Ex Vivo Immune System Regulatory Properties of Boswellia serrata Extracts. *Oxid Med Cell Longev*. 2017;2017:7468064
113. Cafaro G, **Alunno A**, Vaentn V, Leone MC, Marcucci E, Bartolon E, Ger R. The onset site of rheumatoid arthritis: the joints or the lung? *Reumatismo*. 2016 Dec 31;68(4):167-175

114. Quartuccio L, Badn C, Barton E, Pror R, Carubb F, **Alunno A**, Gandofo S, Gattamata A, Gacome R, Ger R, Vaesen G, Bombardier S, De Vita S; GRIS Group (Gruppo di Ricerca Italiana sulla Sindrome di Sjögren). Correlation between ESSDAI and CnESSDAI in a real-life cohort of patients with Sjögren's syndrome. *Clin Exp Rheumatol*. 2017 May-Jun;35(3):546-547
115. Barton E, Gonzalez-Gay MA, Scire C, Castaneda S, Ger R, Lopez-Longo FJ, Martinez-Barró J, Govoni M, Furn F, Pina T, Iannone F, Gannin M, Nuño L, Quartuccio L, Ortego-Centeno N, **Alunno A**, Specker C, Montecucco C, Trantafylas K, Ba duzz S, S Fuentes-Gra do WA, Paoazz G, Brav E, Schwartng A, Per to R, Russo A, Sem C, Saketkoo LA, Fusaro E, Pars S, Pp tone N, Francesch n F, Cavazzana I, Ner R, Barsott S, Codu o V, Cavagna L. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. *Autoimmun Rev*. 2017 Mar;16(3):253-257
116. Antognon F, Lanza M, Po F, Buccon M, Santne C, Capro G, Iannare R, Lupd G, Dam an E, Beghe D, **Alunno A**, Magg F. Polar extracts from the berry-like fruits of *Hypericum androsaemum* L. as a promising ingredient in skin care formulations. *J Ethnopharmacol*. 2017 Jan 4;195:255-265
117. Barton E, Pucc G, Cannare F, Battista F, **Alunno A**, Guan M, Cafaro G, Ger R, Schac G. Central Hemodynamics and Arterial Stiffness in Systemic Sclerosis. *Hypertension*. 2016 Dec;68(6):1504-1511
118. Bucc E, Terenz R, La Pag a GM, Gentesch S, Trpo A, Tan C, **Alunno A**. One year in review 2016: pathogenesis of rheumatoid arthritis. *Clin Exp Rheumatol*. 2016 Sep-Oct;34(5):793-801
119. Carubb F, Cpran P, D Benedetto P, Rusctt P, **Alunno A**, Ger R, Gacome R. Persistence of focal lymphocytic salivary glanditis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF. *Clin Exp Rheumatol*. 2016 Nov-Dec;34(6):1123-1124
120. Montanucc P, Pescara T, Pennon I, **Alunno A**, Bston O, Torone E, Luca G, Ger R, Basta G, Cafore R. Functional Profiling of Human Umbilical Cord-Derived Adult Mesenchymal Stem Cells in Obese/Diabetic Versus Healthy Women. *Curr Diabetes Rev*. 2016 Jun 28. [Epub ahead of print]
121. **Alunno A**, Barton E, Bston O, Ger R, Caneparo V, Carubb F, Landofo S. Relevance of Interferon-Inducible Protein-16 Rather than Anti-Interferon-Inducible Protein-16 Autoantibodies as a Clinical and Pathogenic Biomarker in Primary Sjögren's Syndrome: Comment on the Article by Baer et al. *Arthritis Care Res (Hoboken)*. 2017 Mar;69(3):453-454
122. Capro G, **Alunno A**, Beghe D, Banco A, Bramucc M, Frezza C, Iannare R, Papa F, Quassnt L, Sagratn G, Trin B, Vendtt A, Vttor S, Magg F. Polar Constituents and Biological Activity of the Berry-Like Fruits from *Hypericum androsaemum* L. *Front Plant Sci*. 2016 Mar 1;7:232.
123. **Alunno A**, Caneparo V, Carubb F, Bston O, Caterb S, Garg o M, Barton E, Landofo S, Ger R. Interferon gamma-inducible protein 16 (IFI16) and anti-IFI16 antibodies in primary Sjögren's syndrome: findings in serum and monosalivary glands. *Reumatismo*. 2015 Dec 30;67(3):85-90
124. **Alunno A**, Ibbma-Mannesch L, Bston O, Rosa I, Caterb S, Ger R, Manett M. Mobilization of lymphatic endothelial precursor cells and lymphatic neovascularization in primary Sjögren's syndrome. *J Cell Mol Med*. 2016 Apr;20(4):613-22
125. **Alunno A**, Carubb F, Bston O, Caterb S, Barton E, D Benedetto P, Cpran P, Gacome R, Ger R. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study. *Clin Exp Immunol*. 2016 Jun;184(3):284-92
126. Quartuccio L, Badn C, Bombardier S, Pror R, Vaesen G, Barton E, **Alunno A**, Ger R, Carubb F, Gacome R, De Vita S. The Need to Target Mucosa-Associated Lymphoid Tissue for Preventing Lymphoma in Rheumatoid Factor-Positive Patients With Sjögren's Syndrome: Comment on the Article by Nocturne et al. *Arthritis Rheumatol*. 2016 May;68(5):1318-9
127. Montanucc P, **Alunno A**, Basta G, Bston O, Pescara T, Caterb S, Pennon I, Bin V, Ger R, Cafore R. Restoration of tissue subsets of patients with type 1 diabetes mellitus by microencapsulated human umbilical cord Wharton jelly-derived mesenchymal stem cells: An in vitro study. *Clin Immunol*. 2016 Feb;163:34-41.
128. **Alunno A**, Carubb F, Cafaro G, Pucc G, Battista F, Barton E, Gacome R, Schac G, Ger R. Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis. *Expert Opin Biol Ther*. 2015;15(12):1727-37
129. **Alunno A**, Caneparo V, Bston O, Caterb S, Terenz R, Garg o M, Barton E, Manzo A, Landofo S, Ger R. Circulating Interferon-Inducible Protein IFI16 Correlates With Clinical and Serological Features in Rheumatoid Arthritis. *Arthritis Care Res (Hoboken)*. 2016

- Apr;68(4):440-5
130. **Alunno A**, Caneparo V, Carubb F, Bston O, Caterb S, Barto on E, Gacome R, Garg o M, Lando fo S, Ger R. Interferon gamma-nducbe prote n 16 n primary Sjögren's syndrome: a nove payer n d sease pathogenes s? *Arthrt s Res Ther*. 2015 Aug 14;17:208
 131. P cerno V, Ferro F, Ad no f A, Va ent n E, Tan C, **Alunno A**. One year n review: the pathogenes s of rheumat o d arthrt s. *C n Exp Rheumato*. 2015 Ju -Aug;33(4):551-8
 132. Quartucc o L, Ba d n C, Barto on E, Pror R, Carubb F, Corazza L, **Alunno A**, Co afrancesco S, Luc ano N, Gacome R, Ger R, Va es n G, Bombard er S, De Vta S. Ant-SSA/SSB-negat ve Sjögren's syndrome shows a ower prevaence of ymphopro ferat ve man festat ons, and a ower rsk of ymphoma evo uton. *Auto mmun Rev*. 2015 Nov;14(11):1019-22
 133. **Alunno A**, Carubb F, Bston O, Caterb S, Barto on E, Mrabe G, Cannar e F, C pran P, Gacome R, Ger R. T Regu atory and T He per 17 Ce s n Prmary Sjögren's Syndrome: Facts and Perspect ves. *Med ators Inf amm*. 2015;2015:243723
 134. Caterb S, Bston O, **Alunno A**, Barto on E, Ger R. Ant cyc c Ctru nated Pept de Ant bod es n Pat ents wth Rheumat c D seases other than Rheumat o d Arthrt s: C n ca or Pathogen c S gn f cance? *J Rheumato*. 2015 Jun;42(6):1063-4
 135. Iaccar no L, Barto on E, Ger R, **Alunno A**, Barsott S, Cafaro G, Gatto M, Ta ar co R, Tr po A, Zen M, Ner R, Dor a A. Drugs n nduct on and treatment of d opath c nfammatory myopath es. *Auto Immun H gh ghts*. 2014 Oct 19;5(3):95-100
 136. Terenz R, Santobon G, Barto on E, **Alunno A**, Lucco F, Ger R. Corre at on between c nmetrc approach and German US7 score n rheumat o d arthrt s pat ents treated wth toc zumab: a p ot study. *C n Exp Rheumato*. 2015 May-Jun;33(3):445
 137. **Alunno A**, Manett M, Caterb S, Ibba-Mannesch L, Bston O, Barto on E, Va ent n V, Terenz R, Ger R. A tered mmunoregu at on n rheumat o d arthrt s: the ro e of regu atory T ce s and profammatory Th17 ce s and therapeut c mp cat ons. *Med ators Inf amm*. 2015;2015:751793
 138. **Alunno A**, Ibba-Mannesch L, Bston O, Rosa I, Caterb S, Ger R, Manett M. Teocytes n m nor sa vary gands of prmary Sjögren's syndrome: assoc at on wth the extent of nfamm at on and ectop c ympho d neogenes s. *J Ce Mo Med*. 2015 Ju ;19(7):1689-96
 139. Cannar e F, Va ent n V, Mrabe G, **Alunno A**, Terenz R, Lucco F, Ger R, Barto on E. Card ovascu ar d sease n system c sc eros s. *Ann Trans Med*. 2015 Jan;3(1):8
 140. Barto on E, Ba d n C, Sch ac G, Quartucc o L, Pror R, Carubb F, B n V, **Alunno A**, Bombard er S, De Vta S, Va es n G, Gacome R, Ger R. Card ovascu ar d sease rsk burden n prmary Sjögren's syndrome: resuts of a popu at on-based mut centre cohort study. *J Intern Med*. 2015 Aug;278(2):185-92
 141. **Alunno A**, Bston O, Caterb S, Barto on E, Cafaro G, Ger R. Serum nter leuk n-17 n prmary Sjögren's syndrome: assoc at on wth d sease durat on and parot d gland swe ng. *C n Exp Rheumato*. 2015 Jan-Feb;33(1):129
 142. Petr o MG, Ronchett S, Rcc E, **Alunno A**, Ger R, Nocent n G, Rccard C. GITR+ regu atory T ce s n the treatment of auto mmune d seases. *Auto mmun Rev*. 2015 Feb;14(2):117-26
 143. Perco n E, Gabre E, **Alunno A**, Barto on Bocc E, Perto S, Chow SK, Cenc E, Casadeva A, Ger R, Vecch are A. Funct ona mprovement of regu atory T ce s from rheumat o d arthrt s subjects nduced by capsu ar polysacchar de g ucurooxy omannoga actan. *PLoS One*. 2014 Oct 22;9(10):e111163
 144. Carubb F, **Alunno A**, C pran P, Barto on E, Ba d n C, Quartucc o L, Pror R, Va es n G, De Vta S, Bombard er S, Ger R, Gacome R. A retrospect ve, mut center study eva uat ng the prognost c va ue of m nor sa vary g and h sto gy n a arge cohort of pat ents wth prmary Sjögren's syndrome. *Lupus*. 2015 Mar;24(3):315-20
 145. Quartucc o L, Iso a M, Ba d n C, Pror R, Barto on E, Carubb F, Gregorac G, Gando fo S, Sa v n S, Luc ano N, M nnt A, **Alunno A**, Gacome R, Ger R, Va es n G, Bombard er S, De Vta S. C nca and bo ogca dfferences between cryogobu naem c and hypergammagobu naem c purpura n prmary Sjögren's syndrome: resuts of a arge mut centre study. *Scand J Rheumato*. 2015;44(1):36-41
 146. Nocent n G, **Alunno A**, Petr o MG, Bston O, Barto on E, Caterb S, Ronchett S, Mg orat G, Rccard C, Ger R. Expans on of regu atory GITR+CD25 ow/-CD4+ T ce s n system c upus erythematosus pat ents. *Arthrt s Res Ther*. 2014 Sep 26;16(5):444
 147. Barto on E, **Alunno A**, Bston O, Caterb S, Lucco F, Santobon G, Mrabe G, Cannar e F, Ger R. Characterzat on of crcu at ng endothe a m cropart ces and endothe a damage? *Rheumat o gy (Oxford)*. 2015 Mar;54(3):536-44
 148. **Alunno A**, Carubb F, Barto on E, Bston O, Caterb S, C pran P, Gacome R, Ger R. Unmask ng the pathogen c ro e of IL-17 ax s n prmary Sjögren's syndrome: a new era for therapeut c target ng? *Auto mmun Rev*. 2014 Dec;13(12):1167-73
 149. Carubb F, **Alunno A**, C pran P, Barto on E, Ccca F, Tro o G, Ger R, Gacome R.

- Rituximab in primary Sjögren's syndrome: a ten-year journey. *Lupus*. 2014 Nov;23(13):1337-49
150. **Alunno A**, Montanucci P, Bstn O, Basta G, Caterb S, Pescara T, Pennon I, Bn V, Barton E, Ger R, Caafore R. In vitro immunomodulatory effects of microencapsulated umbilical cord Wharton jelly-derived mesenchymal stem cells in primary Sjögren's syndrome. *Rheumatology (Oxford)*. 2015 Jan;54(1):163-8
 151. Carubb F, **Alunno A**, Cpran P, D Benedetto P, Ruscitti P, Berarducci O, Barton E, Bstn O, Caterb S, Ccca F, Troo G, Ger R, Gacome R. Is minor sialometry and biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: a retrospective study. *Semin Arthritis Rheum*. 2014 Dec;44(3):314-24
 152. **Alunno A**, Carubb F, Caterb S, Bstn O, Barton E, Gacome R, Ger R. The role of T helper 17 cell subsets in Sjögren's syndrome: similarities and differences between mouse model and humans. *Ann Rheum Dis*. 2014 Jun;73(7):e42
 153. Moretti S, Menca E, Voce P, More S, Cantare S, Sponzone M, Coe A, Faiano F, Orabona C, Alunno A, de Base D, Bn V, Mame MG, Fetti S, Ger R, Macchiaro A, Meo RM, Tan G, Santoro M, Puccetti P, Avena N, Puxeddu E. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressive tumor microenvironment. *J Clin Endocrinol Metab*. 2014 May;99(5):E832-40
 154. **Alunno A**, Carubb F, Bstn O, Caterb S, Barton E, Bgerna B, Pacini R, Beghe D, Cpran P, Gacome R, Ger R. CD4(-)CD8(-) T cells in primary Sjögren's syndrome: association with the extent of glandular involvement. *J Autoimmun*. 2014 Jun;51:38-43
 155. Faiano A, Manca V, Barton E, **Alunno A**, Ger R. Diagnosis and classification of autoimmune hypophysitis. *Autoimmun Rev*. 2014 Apr-May;13(4-5):412-6
 156. Badini C, Pepe P, Quartuccio L, Pror R, Barton E, **Alunno A**, Gattamata A, Maset M, Modest M, Tavon A, De Vita S, Ger R, Vaesni G, Bombardieri S. Primary Sjögren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. *Rheumatology (Oxford)*. 2014 May;53(5):839-44
 157. Carubb F, Cpran P, Marre A, Benedetto P, Ruscitti P, Berarducci O, Pantano I, Lakou V, Avaro S, **Alunno A**, Manzo A, Ccca F, Ger R, Troo G, Gacome R. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multicenter, follow-up study. *Arthritis Res Ther*. 2013 Oct 30;15(5):R172.
 158. Quartuccio L, Isoa M, Badini C, Pror R, Barton Boccia E, Carubb F, Maset M, Gregorac G, De Amico V, Savini S, De Marchi G, Luciano N, Coafrancesco S, **Alunno A**, Gacome R, Ger R, Vaesni G, Bombardieri S, De Vita S. Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. *J Autoimmun*. 2014 Jun;51:75-80
 159. **Alunno A**, Bstn O, Barton Boccia E, Caterb S, Bgerna B, Puccini A, Tabarrini A, Mannucci R, Beghe D, Faiano B, Ger R. IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren's syndrome. *Reumatismo*. 2013 Oct 31;65(4):192-8
 160. Pror R, Gattamata A, Modest M, Coafrancesco S, Frisenda S, Minetti A, Framarino-de-Maatesta M, Maset M, Quartuccio L, De Vita S, Barton E, **Alunno A**, Ger R, Strigini F, Badini C, Tan C, Mosca M, Bombardieri S, Vaesni G. Outcome of pregnancy in Italian patients with primary Sjögren's syndrome. *J Rheumatol*. 2013 Jun;40(7):1143-7
 161. **Alunno A**, Petrillo MG, Nocentini G, Bstn O, Barton E, Caterb S, Bianchini R, Badini C, Nicoletti I, Riccardi C, Ger R. Characterization of a new regulatory CD4+ T cell subset in primary Sjögren's syndrome. *Rheumatology (Oxford)*. 2013 Aug;52(8):1387-96
 162. Bizzaro N, Barton E, Morozzi G, Mangano S, Rocca V, Sabatini P, Fippini M, Tampoia M, Afeita A, Sebastian G, Apin C, Bn V, Bstn O, **Alunno A**, Ger R; Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA Group). Anticyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. *Arthritis Res Ther*. 2013 Jan 22;15(1):R16
 163. Percon E, **Alunno A**, Gabre E, Barton E, Cenci E, Chow SK, Bstn G, Casadevall A, Ger R, Vecchiarelli A. The microbial capsular polysaccharide galactosylmannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients. *PLoS One*. 2013;8(1):e53336
 164. **Alunno A**, Nocentini G, Bstn O, Petrillo MG, Barton Boccia E, Ronchetti S, Lo Vago E, Riccardi C, Ger R. Expansion of CD4+CD25-GITR+ regulatory T cell subset in the peripheral blood of patients with primary Sjögren's syndrome: correlation with disease activity. *Reumatismo*. 2012 Dec 11;64(5):293-8
 165. **Alunno A**, Bstn O, Barton E, Caterb S, Bgerna B, Tabarrini A, Mannucci R, Faiano B,

- Ger R. IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate various glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. *Ann Rheum Dis*. 2013 Feb;72(2):286-92
166. Barton E, **Alunno A**, Santobon G, Ger R. Beneficial cardiovascular effects of low-dose glucocorticoid therapy in inflammatory rheumatic diseases. *J Rheumatol*. 2012 Aug;39(8):1758-60
167. **Alunno A**, Barton E, Bstn O, Nocent G, Ronchetti S, Caterb S, Valent V, Rccard C, Ger R. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. *Clin Dev Immunol*. 2012;2012:823085
168. Barton E, **Alunno A**, Ger R. Primary Sjogren's syndrome as paraneoplastic disorder: a case report. *Clin Exp Rheumatol*. 2012 May-Jun;30(3):454
169. Barton E, **Alunno A**, Bstn O, Bzzaro N, Mgorn P, Morozz G, Doraa A, Math eu A, Lotzner M, Aegr F, Rccer V, Apn C, Gabre A, Tampo a M, Ger R; Forum Interdisciplinare per la Ricerca nella Malattia Autoimmune (FIRMA) Investigators. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. *Autoimmun Rev*. 2012 Sep;11(11):815-20
170. Sch ac G, Barton E, Pucc G, Prrro M, Sett m L, **Alunno A**, Ger R, Mannar no E. Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatment. *Ann Rheum Dis*. 2012 Jun;71(7):1151-6
171. Barton E, Ludov n V, **Alunno A**, Psto a L, Bstn O, Crnò L, Ger R. Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjogren's syndrome. *Lupus*. 2011 Aug;20(9):928-35
172. Bianchi R, Bstn O, **Alunno A**, Petr o MG, Ronchetti S, Sporto ett P, Bocc EB, Nocent G, Ger R, Rccard C. CD4(+) CD25(ow) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. *Eur J Immunol*. 2011 Aug;41(8):2269-78
173. Barton E, **Alunno A**, Bstn O, Ger R. Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested mode of preventive strategy. *Clin Rev Allergy Immunol*. 2013 Feb;44(1):14-
174. Barton E, **Alunno A**, Lucco F, Moscate S, Bscntn D, Santobon G, Ger R. Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. *Expert Rev Cardiovasc Ther*. 2010 Sep;8(9):1309-16
175. Barton E, **Alunno A**, Bstn O, Ger R. How early is the atherosclerotic risk in rheumatoid arthritis? *Autoimmun Rev*. 2010 Aug;9(10):701-7
176. **Alunno A**, Barton E, Nocent G, Bstn O, Ronchetti S, Petr o MG, Rccard C, Ger R. Role of regulatory T cells in rheumatoid arthritis: facts and hypotheses. *Autoimmun Highlights*. 2010 Jun;1(1):45-51
177. Ger R, Vaudo G, Bocc EB, Sch ac G, **Alunno A**, Lucco F, Hjaz R, Mannar no E, Shoenfeld Y. Functional impairment of the arterial wall in primary Sjogren's syndrome: combined action of immunologic and inflammatory factors. *Arthritis Care Res (Hoboken)*. 2010 May;62(5):712-8
178. Barton E, **Alunno A**, Lucco F, Santobon G, Ger R. Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody. *Clin Exp Rheumatol*. 2009 Sep-Oct;27(5):888-9
179. Barton Bocc E, Gordano A, Lucco F, **Alunno A**, Ger R. Crescentic glomerulonephritis and circulating antineutrophil cytoplasmic antibodies in scleroderma: a case report and review of the literature. *Clin Exp Rheumatol*. 2009 Mar-Apr;27(2):385-6
180. Ger R, Nocent G, **Alunno A**, Bocc EB, Bianchi R, Bstn O, Rccard C. Identification of regulatory T cells in systemic lupus erythematosus. *Autoimmun Rev*. 2009 Mar;8(5):426-30
181. Barton Bocc E, Lucco F, Angrsan C, Moscate S, **Alunno A**, Ger R. Accelerated atherosclerosis in systemic lupus erythematosus and other connective tissue diseases. *Expert Rev Clin Immunol*. 2007 Jun;3(4):531-41

CONFERENCES

-Invited speaker

- Conference "Central role of 25(OH)D3. Importance of vitamin D status in the clinical setting". May 5, 2012, Castello de 'Oscano, Perugia. Presentation title: Vitamin D and the immune system.
- Medical-scientific meeting "Chocolate and rheumatic diseases", 26th October 2012, Sala de a Vaccara, Perugia. Presentation title: Chocolate and the immune system.
- E.R.A.S.S. Instructional Course "Update on the medical and surgical treatment of rheumatic diseases". Convitto de la Ca'za, Florence, 29 November-1 December 2012. Presentation title: Non-infectious involvement following biologics therapy in rheumatoid arthritis.
- Conference "Arthritis in rheumatology, autoimmune diseases ten years after", Centro congresso v a

- Mondragone, Monte Porzio Catone, Rome, 4 October 2014. Presentation title: Sjögren's syndrome: pathogenesis in 2014
- IV Post graduate course: diffuse interstitial pneumopathies (P.I.D.), knowing for recognition. Park Hotel Cappuccini, Gubbio, 23-25 October 2014. Presentation title: Rheumatic diseases as a paradigm for the polyautoimmune.
 - The 4th Israel-Italy Meeting, Autoimmunity and Inflammation Cutting Edge. Siena 27-28 September 2015. Presentation title: Novel therapeutic strategies in primary Sjögren's syndrome
 - Annual European Congress of Rheumatology, EULAR 2016, London, United Kingdom, 8-11 June 2016. Presentation title: The role of health professionals in improving shared decision making with young people with RMDs
 - EULAR Young PARE meeting 'Change the future', Rete, Bergamo, 22-24 October 2016, Presentation title: What's catching? Key factors of a good patch
 - Innovative insights into arthritis and its treatment, Turin, 2-3 February 2018. Presentation title: RA and PsA Interactive challenging cases from the young rheumatologists
 - EULAR PARE meeting, Brussels Bergamo, 16-18 February 2018, Presentation title: Barriers to early diagnosis and appropriate treatment for pediatric and young adult RMDs
 - XVII Mediterranean Congress of Rheumatology, Genoa, 12-14 April 2018, Presentation title: Sjögren syndrome today. Management: non-pharmacological aspects and unmet needs
 - Benefits of early diagnosis in rheumatic diseases, Florence 22 September 2018, Presentation title: Early diagnosis and management of rheumatic diseases: the point of view of young rheumatologists of the Italian Society of Rheumatology
 - SIR Educational Course: the laboratory in the diagnosis of rheumatic diseases, Perugia, 27-29 September 2018, Presentation title: Rheumatoid arthritis and differential diagnosis with spondyloarthritis
 - EULAR Postgraduate Course, Budapest, Hungary, 1-3 October 2018, Presentation title: Clinical spectrum of Sjögren's syndrome
 - 2018 ACR/ARHP Annual Meeting, Chicago, IL, USA, 21-24 October 2018 Presentation title: Evolving clinical care pathways in RA: patients at the center?
 - XLV National Congress of the Italian Society of Rheumatology, Rimini, 21-24 November 2018 Presentation title: The doctor-patient relationship in the age of interactive medicine: benefits and critiques
 - Precision comes first, Milan February 15-16, 2019. Workshop title "The patient at the center"
 - New insights in rheumatoid arthritis on the cutting edge of research. Florence, 5-6 April 2019. Presentation title: Disease evolution, from very early RA to advanced RA
 - III Ovidian Days of Rheumatology, Suisa, 18-19 October 2019. Presentation title: Rheumatoid arthritis update on pathogenesis
 - Biomarkers in Rheumatic Diseases 10th GISEA International Meeting, Rome 13-14 December 2019. Presentation title: Sjögren's syndrome
 - Italian Society of Rheumatology Course "The interpretation of laboratory exams in rheumatic diseases. Perugia, 10-12 September 2020. Presentation title: Autoantibodies in rheumatoid arthritis
 - 22nd Annual Congress of Croatian Society for Rheumatology (virtual event) 16-17 October 2020. Presentation title: Clinical aspects, biomarkers and therapeutic strategies in primary Sjögren's syndrome
 - "My brothers: face the future by challenging the past" (virtual event) 21 May 2021. Presentation title: Targeting inflammasomes in rheumatic diseases
 - Annual European Congress of Rheumatology "EULAR 2021" (virtual event) Presentation titles: EULAR Points to Consider on COVID-19 pathophysiology and immunomodulatory therapies from the Rheumatology Perspective; Highlights from the Scientific Programme, PARE session
 - V Ovidian Days of Rheumatology, Suisa, 29-30 October 2021. Presentation title: Pathogenesis of SLE, targets for targeted therapy
 - "Rheumatology Ward Round" (virtual event), 16 February 2022, Presentation title: Workup of patients with proteuria in the setting of RMDs
 - "Up to date in European rheumatic diseases, Manfredonia, 1-2 April 2022. Presentation title: ILD and rheumatic diseases, the role of antifibrotic therapy.
 - Annual European Congress of Rheumatology, EULAR, Copenhagen, Denmark, 2-5 June 2022. Presentation title: Conventional synthetic (cs) DMARDs: a milestone in therapy; Young people with RMDs and rheumatology research: a story of success.

-Chairperson

- Annual European Congress of Rheumatology, EULAR 2014, Paris, France, 11-14 June 2014. Session title: Cytokines and inflammatory mediators.
- Annual European Congress of Rheumatology, EULAR 2015, Rome, Italy, 10-13 June 2015. Session title: Evidence based medicine. To design and understand clinical trials and meta-analyses

- Annual European Congress of Rheumatology, EULAR 2017, Madrid, Spain, 14-17 June 2017. Title of the sessions: New treatments in SLE, Sjögren and APS; RA treatment in patients wanting to become pregnant- interactive session; Barrier free employment for young people with RMDs
- Annual European Congress of Rheumatology, EULAR 2018, Amsterdam 13-16 June 2018. Title of the sessions: Present and future treatments for SLE, Sjögren and APS; Inclusive school environment for people with RMDs: The challenges of rheumatology training in the competitive learning environment.
- Topical Immunoreumatology 2019, Brussels 25-26 October 2019. Session title: Sjögren's syndrome
- XLVI National Congress of the Italian Society of Rheumatology, Rome, 27-30 November 2019. Title of the Round Table: Cardiovascular involvement in rheumatic diseases: Why talk about Cardio-Rheumatology? Title of the poster session: Idiopathic inflammatory myopathies

-Participant

Dr Alunno participated in over 60 national and international conferences and courses.

-Organiser

Member of the organising committee of the 6th EULAR Immunology Course (Amsterdam 2023)

-Congress abstracts

Since 2007 Dr Alunno co-authored over 150 abstracts, 100 of which as first author, presented at National and International Congresses

Awards

- 2009 Young Investigator award at the National Congress of the Italian Society of Rheumatology
- 2010 Young Investigator award at the National Congress of the Italian Society of Rheumatology
- 2011 Best oral presentation award at the 1st International Congress on Controversies in Rheumatology and Autoimmunity
- 2011 Young Investigator award at the National Congress of the Italian Society of Rheumatology
- 2013 Best poster presentation award at the 2nd International Congress on Controversies in Rheumatology and Autoimmunity
- 2014 Young Investigator award at the National Congress of the Italian Society of Rheumatology
- 2015 Best oral presentation award at the 3rd International Congress on Controversies in Rheumatology and Autoimmunity
- 2016 Best oral presentation award at the 10th European Congress on Systemic Lupus Erythematosus
- 2016 Young Investigator award at the National Congress of the Italian Society of Rheumatology
- 2017 Young Investigator award at the National Congress of the Italian Society of Rheumatology
- 2019 Italian Society of Rheumatology Award at the 5th International Congress on Controversies in Rheumatology and Autoimmunity

Affiliations/memberships

- Italian Society of Rheumatology: member since 2010
- Young Rheumatologists committee within the Italian Society of Rheumatology (SIRyoung): Founder (2017), Chair 2017-2018 Past-Chair 2018-2020
- Emerging EULAR Network (EMEUNET): Working Group Member 2013-2016, Chair-elect 2017-2018, Chair 2018-2019, Past-Chair 2019-2020
- Italian Foundation for Research on Arthritis (FIRA Onus): member of the scientific committee since 2016-2022
- Royal Society of Medicine member since 2021
- European Lupus Society (SLEuro) member since 2021

Study groups and Task Forces

- Co-founder and member of the Italian Society of Rheumatology Study Group on Sjögren's syndrome
- Member of the Italian Society of Rheumatology Study Group on antiphospholipid syndrome
- Member of the EULAR Study Group on Sjögren's syndrome (eSSentia)
- Member of the Subcommittees for live courses, online courses and CME&Training of the EULAR Education Committee
- Member of the European consortium "Harmonization and integrative analysis of regional, national and international cohorts on primary Sjögren's syndrome (pSS) towards improved stratification, treatment and health policy making" (Coordinator Prof Athanasios Tzioufas)
- Member of the Sjögren's syndrome Big Data project (Coordinator Prof Manuel Ramos-Casas)
- EULAR Task Forces:

1) EMEUNET representative:

1a) 2019 update of the recommendations for the management of SLE (Convenor Prof D.

Boumpas) [Ann Rheum D s. 2019 do : 10.1136/annrheumd s-2019-215089]

1b) PtC for the use of magnetic guidance interventional procedures in patients with RMDs (Convenor Dr. C. Dejaco) [Ann Rheum D s. 2022 do : 10.1136/annrheumd s-2021-221261]

1c) PtC for minimum reporting requirements in synovial tissue research in rheumatology (Convenors Prof A. Ferrer, Dr. A Najm) [Ann Rheum D s. 2022 do : 10.1136/annrheumd s-2021-221875]

2) Fellow:

2a) PtC for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis (Convenor Prof A. Boonen) [Ann Rheum D s. 2021 do : 10.1136/annrheumd s-2020-219523]

2b) PtC on the use of immunomodulatory therapies in COVID-19 (Convenors Prof X. Marotte, Prof D. McGonagle) [Ann Rheum D s. 2022 do : 10.1136/annrheumd s-2021-221366; Ann Rheum D s. 2021 do : 10.1136/annrheumd s-2020-219724]

2c) PtC for the assessment of competences in rheumatology specialty training (Convenor Prof F. Svera) [Ann Rheum D s. 2021 do : 10.1136/annrheumd s-2020-218015]

2d) 2021 update of the recommendations for the management and vaccination of people with RMDs in the context of SARS-CoV-2 (Convenor Prof. R. Landewé) [Ann Rheum D s. 2022 do : 10.1136/annrheumd s-2021-222006]

2e) PtC: EULAR-UEMS standards for the training of European rheumatologists (Convenor Prof C. Edwards) [Manuscript with the EULAR Council for revision]

3) Convenor:


3a) PtC for including the perspective of young patients with inflammatory arthritis into patient-reported outcomes measures (Co-convenor Dr Pau Studenč) [RMD Open. 2022 do : 10.1136/rmdopen-2022-002576]

4) Regular member:

4a) Gender equity in academic rheumatology (Convenor Prof L. Coates) [RMD Open. 2022 do : 10.1136/rmdopen-2022-002518]

I hereby authorize the use of my personal data in accordance to the GDPR 679/16 "European regulation on the protection of personal data"

L'Aquila, 23 November 2022


Alessia Alunno, MD PhD